Abstracts tagged "Lupus nephritis"

Abstract Number: 0849 • ACR Convergence 2023
Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus
Sarit Pattanaik¹, Ratnadeep Mukherjee², Rina Tripathy³, Birendra Prusty⁴, Balachandran Ravindran⁵ and Bidyut Das⁶, ¹SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ²Norwegian Institute of Public Health, Oslo, Norway, ³Sardar Vallabhbhai Patel Post Graduate Institute of Pediatrics, Cuttack, India, ⁴Fisheries & Animal Resources Development Department, Phulbani, India, ⁵Institute of Life Sciences, Bhubaneswar, India, ⁶SCB medical college, Cuttack, India
Background/Purpose: SLE is one of the leading causes of death in young females suffering from autoimmune disorders. Nephritis, afflicts 60-70% of patients which contribute significantly…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…
Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: 2443 • ACR Convergence 2023
Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Junpeng Zhao¹, Liming Li¹, Xiwei Feng¹, Huiqi Yin¹ and Qianjin Lu², ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Genetic variations in the OX40 ligand (OX40L) locus have been implicated in the susceptibility to systemic lupus erythematosus (SLE). Notably, the blockade of OX40L…
Abstract Number: 0180 • ACR Convergence 2023
Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review
Shivani Garg¹, Brianna Boderman², Nadia Sweet², Daniel Montes³, Brad Astor², S. Sam Lim⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Mayo Clinic, Rochester, MN, ⁴Emory University, Atlanta, GA
Background/Purpose: Lupus results in 58% more organ damage in people of Black race in the US compared to African descendants living in 11 other developed…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…
Abstract Number: 2020 • ACR Convergence 2023
Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice
Francesca Cardwell¹, Susan Elliott¹, Megan R.W. Barber², Kim Cheema², Sydney George³, Adrian Boucher³ and Ann Clarke⁴, ¹University of Waterloo, Waterloo, ON, Canada, ²University of Calgary, Calgary, AB, Canada, ³GlaxoSmithKline, Mississauga, ON, Canada, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: LN is a major cause of morbidity and mortality and develops in up to 60% of adult SLE patients. The experiences of patients with…
Abstract Number: 2445 • ACR Convergence 2023
Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Dayvia Russell¹, Sandra Sanchez², Evelyn Bruner² and Jim Oates², ¹Ralph H. Johnson VA Medical Center, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) constitutes one of the most severe manifestations of systemic lupus erythematosus (SLE). Evidence points to endothelial nitric oxide synthase (eNOS) uncoupling,…
Abstract Number: 0544 • ACR Convergence 2023
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
Ranjan Gupta¹, Amita Aggarwal², Avinash Jain³, Liza Rajasekhar⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Bidyut Das⁹ and Manish Rathi¹⁰, ¹All India Institute of Medical Sciences, New Delhi, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ³SMS Medical College, Lucknow, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁶St. John's National Academy of Health Science, Bangalore, India, ⁷Christian Medical College, Vellore, India, ⁸Govt of West Bengal, Kolkata, India, ⁹SCB medical college, Cuttack, India, ¹⁰Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Anti-dsDNA antibodies (ADA) are traditionally measured by ELISA and are associated with Lupus nephritis (LN). Testing by immunoline assay (IL) provides additional information on…
Abstract Number: 0851 • ACR Convergence 2023
Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms
Abhimanyu Amarnani¹, Doua Azzouz², MacIntosh Cornwell³, David Mieles³, Peter Izmirly⁴, Jill Buyon⁵, Kelly Ruggles⁶ and Gregg Silverman⁵, ¹NYU Langone Medical Center, New York, NY, ²NYU Langone Health ( School of medicine), New York, NY, ³New York University, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY, ⁶NYU Langone, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with gut microbiota dysbiosis, and community imbalance can coincide with flares of Lupus nephritis (LN). Herein, we sought…
Abstract Number: 1094 • ACR Convergence 2023
“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Christopher Macko¹, Patty Chen², Roger Santos³, Nirmala Ramalingam⁴, Nicole Tran⁵ and Sijie Zheng⁶, ¹Kaiser Oakland Internal Medicine Residency, Piedmont, CA, ²Kaiser Oakland Medical Center Department of Rheumatology, Orinda, CA, ³Kaiser East Bay Department of Pharmacy, Oakland, CA, ⁴Kaiser Oakland Medical Center Department of Graduate Medical Education, Oakland, CA, ⁵Kaiser Oakland Department of Adult and Family Medicine, Oakland, CA, ⁶Kaiser Oakland Medical Center Department of Nephrology, Oakland, CA
Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…
Abstract Number: 1505 • ACR Convergence 2023
Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
Gabriel Contreras¹, Matt Baker², Lucy Hodge² and Ernie Yap², ¹University of Miami Health System, Miami, FL, ²Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada
Background/Purpose: Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin…

« Previous Page
1
…
6
7
8
9
10
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.